Results 211 to 220 of about 2,912,674 (304)

Role of Bruton's Tyrosine Kinase in B Cell Development

Clinical and Developmental Immunology, 2001
Alex Maas, Rudolf W. Hendriks
doaj   +1 more source

Proteasome inhibitor, ixazomib prevents topoisomerase‐I degradation and reverses irinotecan resistance in colorectal cancer

Molecular Oncology, EarlyView.
Ixazomib inhibits proteasome‐mediated degradation of topoisomerase I induced by irinotecan, thereby restoring drug sensitivity and promoting tumor cell death in colorectal cancer. Irinotecan, a topoisomerase I (topoI) inhibitor, is widely used for colorectal cancer, but resistance remains a major clinical challenge.
Yuho Ebata, Koji Ando, Hirofumi Hasuda, Koshi Mimori, Elizabeth C. Unan, Siddhartha Pulukuri, Aahana Tiku, Allison Berger, Eiji Oki, Ajit Bharti, Tomoharu Yoshizumi   +10 more
wiley   +1 more source

Antigen selection reflected in the subclonal architecture of the B-cell receptor immunoglobulin gene repertoire in splenic marginal zone lymphoma. [PDF]

Hemasphere
Zaragoza-Infante L, Agathangelidis A, Iatrou A, Junet V, Pechlivanis N, Karypidou M, Koletsa T, Karakatsoulis G, Bruscaggin A, Davis Z, Spina V, Verney A, Polychronidou E, Psomopoulos F, Oscier D, Traverse-Glehen A, Papaioannou M, Ghia P, Rossi D, Chatzidimitriou A, Stamatopoulos K.   +20 more
europepmc   +1 more source

Checkpoint blockade and the stem‐like T cell trade‐off

Molecular Oncology, EarlyView.
Stem‐like T cells are key to the success of programmed cell death protein 1 (PD1) blockade, as they sustain long‐term anti‐tumor response by continuously generating effector CD8+ T cells. However, how these cells are maintained in cancer is not fully understood. Hor et al.
Julie M. Mazet, Johanna A. Joyce
wiley   +1 more source

The cytoskeletal control of B cell receptor and integrin signaling in normal B cells and chronic lymphocytic leukemia. [PDF]

FEBS Lett
Pethe A, Hartmann TN.
europepmc   +1 more source

B-Cell Receptor Complex [PDF]

, 2020
openaire   +1 more source

Molecular cancer prevention: Intercepting disease

Molecular Oncology, EarlyView.
Oncological practice must evolve, from treating established tumours to proactive cancer interception before clinical manifestation. This will require mechanistic insight into tumour initiation, validated biomarkers of early disease development and redesigned clinical trials, enabling cancer interception to become a core pillar of oncology with the ...
Charlotte Grieco, Tej Pandya, Charles Swanton   +2 more
wiley   +1 more source

B-cell Receptor Silencing Reveals the Origin and Dependencies of High-Grade B-cell Lymphomas with MYC and BCL2 Rearrangements. [PDF]

Blood Cancer Discov
Varano G, Lonardi S, Sindaco P, Pietrini I, Morello G, Balzarini P, Vit F, Neuman H, Bertolazzi G, Brambillasca S, Parr NC, Chiarini M, Bellesi S, Maiolo E, Giampaolo S, Mainoldi F, Selvarasa V, Arima H, Pellegrini V, Pagani C, Bugatti M, Ranise C, Taddei TM, Sonoki T, Thanasi H, Morlacchi E, Segura-Garzon D, Albertini E, Daffini R, Sivacegaram A, Yang H, Li Y, Cancila V, Cicio G, Robusto M, Leuzzi B, Andronache A, Trifiro P, Riboni M, Minardi SP, Bonnal RJP, Gonzalez CL, Visco E, Capaccio P, Torretta S, Pignataro L, Almici C, Varasi M, Larocca LM, Siebert R, Falini B, Ferreri AJM, Tucci A, Lorenzini D, Cabras AD, Pruneri G, Di Napoli A, Ungari M, Pizzi M, Hohaus S, Mercurio C, Song JY, Chan WC, Lorenzi L, Bomben R, Ponzoni M, Mehr R, Tripodo C, Facchetti F, Casola S.   +69 more
europepmc   +1 more source

Metastasis on pause: How dormant tumor cells stay hidden within the tumor microenvironment and evade immune surveillance

Molecular Oncology, EarlyView.
Dormant cancer cells can hide in distant organs for years, evading treatment and the immune system. This review highlights how signals from the surrounding tissue and immune environment keep these cells inactive or trigger their reawakening. Understanding these mechanisms may help develop therapies to eliminate or control dormant cells and prevent ...
Kanishka Tiwary, Jose Javier Bravo‐Cordero   +1 more
wiley   +1 more source

A prognostic model of 8-T/B cell receptor-related signatures for hepatocellular carcinoma. [PDF]

Discov Oncol
Zuo X, Li H, Xie S, Shi M, Guan Y, Liu H, Yan R, Zheng A, Li X, Liu J, Gan Y, Shi H, Chen K, Jia S, Chen G, Liao M, Wang Z, Han Y, Liao B.   +18 more
europepmc   +1 more source